USP25 and diabetes mellitus: The results showed that intravitreal injection of AAV-sh-USP25 alleviated diabetes-induced retinal inflammation 8 weeks after STZ injection, as evidenced by reduced expression levels of Iba-1, MCP-1, IL-1β, and TNF-α (Fig. 2b–k).